Detail
| LncRNA Name | lncRNA-PRAL |
| Synonyms | PRAL, lncRNA-PRAL |
| Region | GRCh38_17:6772831-6776116 Sequence |
| Ensembl | ENSG00000279296 |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | multiple myeloma |
| ICD-0-3 | C42.1 M9732/3 |
| Methods | qPCR, Western blot, Flow cytometry, etc. |
| Sample | cell lines (NCI-H929, ARH77, PRMI8226, OPM2, JJN3) |
| Expression Pattern | down-regulated |
| Function Description | Survival curves showed that MM patients with low PRAL expression had a significantly shorter disease-free survival (DFS) and overall survival (OS) than the patients with high PRAL expression. We further identified and confirmed that miR-210 was the target of PRAL, and miR-210 overexpression overturned the potentiation effect of PRAL on BTZ efficacy. bone morphogenetic protein 2 (BMP2) was confirmed to be the target of miR-210. |
| Pubmed ID | 29944867 |
| Year | 2018 |
| Title | LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. |
| External Links |
| Links for lncRNA-PRAL | GenBank HGNC lncrnadb Noncode |
| Links for multiple myeloma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.